H
Henry M. Wood
Researcher at University of Leeds
Publications - 57
Citations - 2059
Henry M. Wood is an academic researcher from University of Leeds. The author has contributed to research in topics: Cancer & Microbiome. The author has an hindex of 16, co-authored 51 publications receiving 1497 citations. Previous affiliations of Henry M. Wood include King Saud University & Wellcome Trust.
Papers
More filters
Journal ArticleDOI
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli.
Cayetano Pleguezuelos-Manzano,Jens Puschhof,Axel Rosendahl Huber,Arne Van Hoeck,Henry M. Wood,Jason Nomburg,Jason Nomburg,Carino Gurjao,Carino Gurjao,Freek Manders,Guillaume Dalmasso,Paul B. Stege,Fernanda L. Paganelli,Maarten H. Geurts,Joep Beumer,Tomohiro Mizutani,Yi Miao,Reinier van der Linden,Stefan van der Elst,K. Christopher Garcia,Janetta Top,Rob J. L. Willems,Marios Giannakis,Marios Giannakis,Richard Bonnet,Phil Quirke,Matthew Meyerson,Edwin Cuppen,Ruben van Boxtel,Hans Clevers +29 more
TL;DR: A distinct mutational signature in colorectal cancer is described and it is implied that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin-producing pks pathogenicity island.
Journal ArticleDOI
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
Henry Watson,Suparna Mitra,Fiona Croden,M Taylor,Henry M. Wood,SL Perry,Jade A. Spencer,Phil Quirke,Giles J. Toogood,Clare L. Lawton,Louise Dye,Paul M. Loadman,Mark A. Hull +12 more
TL;DR: Omega-3 PUFA supplementation induces a reversible increase in several short-chain fatty acid-producing bacteria, independently of the method of administration, as well as a reversible increased abundance of several genera, including Bifidobacterium and Lactobacillus.
Journal ArticleDOI
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
Susan D. Richman,K Southward,Philip A. Chambers,D Cross,Jennifer H. Barrett,Gemma Hemmings,M Taylor,Henry M. Wood,Gordon G A Hutchins,Joseph M. Foster,Assa Oumie,Karen G. Spink,Sarah Brown,Marc Jones,David J. Kerr,Kelly Handley,Richard Gray,Matthew T. Seymour,Philip Quirke +18 more
TL;DR: HER2‐amplification/overexpression is identifiable by immunohistochemistry, occurring infrequently in stage II–III CRC, rising in stage IV and further in KRAS/BRAF WT tumours, and the value of HER2‐targeted therapy in patients with HER2-amplified CRC must be tested in a clinical trial.
Journal ArticleDOI
Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data
TL;DR: A method that corrects contamination with normal cells and adjusts for genomes of different sizes so that the actual copy number of each region can be estimated, and proves a powerful tool when analysing publicly available data from two cell lines.
Journal ArticleDOI
Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens
Henry M. Wood,Ornella Belvedere,Caroline Conway,Catherine Daly,Rebecca Chalkley,Melissa Bickerdike,Claire McKinley,Phil Egan,Lisa Ross,Bruce E. Hayward,Joanne E. Morgan,Leslie Davidson,Ken MacLennan,T.K. Ong,Kostas Papagiannopoulos,Ian Cook,David J. Adams,Graham R. Taylor,Pamela Rabbitts +18 more
TL;DR: It is confirmed that the next-generation sequencing technique can be used to interrogate DNA from cell lines, fresh frozen material and FFPE samples to assess copy number variation, and it is shown that as little as 5 ng of DNA is needed to generate a copy number karyogram.